1723 related articles for article (PubMed ID: 23687644)
61. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
[TBL] [Abstract][Full Text] [Related]
63. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
[TBL] [Abstract][Full Text] [Related]
64. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
65. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
66. F18-FDG PET-CT analyses of small peripheral adenocarcinoma of the lung.
Takahashi Y; Takashima S; Watanabe S; Tomita Y; Hakucho T; Miyake C; Morimoto D; Hosoki T; Nakanishi K; Higashiyama M
Acta Radiol; 2013 Mar; 54(2):164-8. PubMed ID: 23138022
[TBL] [Abstract][Full Text] [Related]
67. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
68. SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume.
Kim TH; Ji YB; Song CM; Kim JY; Choi YY; Park JS; Tae K
World J Surg Oncol; 2015 Jul; 13():217. PubMed ID: 26179774
[TBL] [Abstract][Full Text] [Related]
69. Incidental focal colorectal ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography.
Cho SH; Kim SW; Kim WC; Park JM; Yoo IeR; Kim SH; Oh ST
World J Gastroenterol; 2013 Jun; 19(22):3453-8. PubMed ID: 23801838
[TBL] [Abstract][Full Text] [Related]
70. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
[TBL] [Abstract][Full Text] [Related]
71. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
72. Utility of FDG PET/CT in the Characterization of Sinonasal Neoplasms: Analysis of Standardized Uptake Value Parameters.
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
AJR Am J Roentgenol; 2018 Dec; 211(6):1354-1360. PubMed ID: 30300005
[TBL] [Abstract][Full Text] [Related]
73. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
74. The role of ¹⁸F-FDG uptake features in the differential diagnosis of solitary pulmonary lesions with PET/CT.
Zhao M; Chang B; Wei Z; Yu H; Tian R; Yuan L; Jin H
World J Surg Oncol; 2015 Sep; 13():271. PubMed ID: 26369407
[TBL] [Abstract][Full Text] [Related]
75. Standardized uptake value and metabolic tumor volume measured by ¹⁸F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma.
Vural GU; Akkas BE; Demirel BB
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):268-73. PubMed ID: 25018135
[TBL] [Abstract][Full Text] [Related]
76. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR.
Rasmussen JH; Fischer BM; Aznar MC; Hansen AE; Vogelius IR; Löfgren J; Andersen FL; Loft A; Kjaer A; Højgaard L; Specht L
Br J Radiol; 2015 Apr; 88(1048):20140655. PubMed ID: 25634069
[TBL] [Abstract][Full Text] [Related]
77. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors.
Luo G; Liu Z; Guo M; Jin K; Xiao Z; Liu L; Xu J; Zhang B; Liu C; Huang D; Hu S; Ni Q; Long J; Yu X
Int J Oncol; 2014 Oct; 45(4):1531-6. PubMed ID: 25096059
[TBL] [Abstract][Full Text] [Related]
78. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.
Sun W; Xu J; Hu W; Zhang Z; Shen W
Colorectal Dis; 2013 May; 15(5):e231-8. PubMed ID: 23384167
[TBL] [Abstract][Full Text] [Related]
79. F-18 fluorodeoxyglucose uptake in a solid pseudopapillary tumor of the pancreas mimicking malignancy.
Shimada K; Nakamoto Y; Isoda H; Maetani Y; Yamashita R; Arizono S; Hirokawa Y; Nitta T; Doi R; Haga H; Togashi K
Clin Nucl Med; 2008 Nov; 33(11):766-8. PubMed ID: 18936608
[TBL] [Abstract][Full Text] [Related]
80. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
